CAMBRIDGE, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive ...
FOSTER CITY, Calif. and CAMBRIDGE, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical ...
CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and ...
Slide it under a stand-up desk, and the JTX MoveLight Walking Treadmill will see you achieve 10,000 steps a day without ignoring your emails When you purchase through links on our site, we may earn an ...
Biotech company Gilead Sciences is in-licensing a preclinical cancer immunotherapy asset that is expected to undergo regulatory review for clinical testing next year. Foster City, California-based ...
Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic ...
CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback